Uterine leiomyoma: treatment with LHRH agonist.
D000328:Adult; D002064:Buserelin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003613:Danazol / Q000627:therapeutic use; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D053685:Laser Therapy; D007889:Leiomyoma / Q000188:drug therapy* / Q000601:surgery; D007986:Luteinizing Hormone / Q000097:blood; D008875:Middle Aged; D011372:Progestins / Q000627:therapeutic use; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000601:surgery
D011372:Progestins; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D003613:Danazol; D002064:Buserelin